SK bioscience announced on the 18th that it has received approval for the clinical phase 1 and phase 3 trials of its 21-valent pneumococcal protein conjugate vaccine candidate, 'GBP410', in China. The company plans to enter phase 3 after completing phase 1 locally. SK bioscience and Sanofi are jointly developing GBP410. In a multinational phase 2 trial, it confirmed equivalent immunogenicity and safety to existing licensed vaccines. CEO Ahn Jae-yong noted, 'The approval of the clinical trial plan in China is another milestone following the expansion of the GBP410 production facility.'
The National Institute of Food and Drug Safety Evaluation (NIFDS) announced on the 18th that the indigenous herb, angelica gigas, has been registered for the first time in the United States Pharmacopeia (HMC). The pharmacopeia serves as a standard reference for quality standards of herbal medicines in the U.S. Angelica gigas is a raw ingredient for Uhwachunsimwon. This registration is expected to facilitate the export of products containing this ingredient to the United States.
Samsung Bioepis has obtained the international certification of 'ISO 37301', an international compliance management system established by the International Organization for Standardization (ISO). This international standard evaluates whether the company has internal processes in place to systematically manage compliance risks and adhere to relevant regulations and ethical standards. With this certification, it has now acquired a total of 5 international standard certifications.
Keeps Biopharma announced on the 18th that its subsidiary, Keeps Biomed, has applied for a domestic patent concerning the formulation of its oral peptide drug delivery platform technology, 'Oraloid™'. According to the company, the patent involves platform technology for delivering peptide drugs orally, focusing on preventing degradation in the gastrointestinal tract and promoting absorption of peptide-based medicines such as insulin and GLP-1 (glucagon-like peptide), which have been challenging to administer orally.
Daewoong Pharmaceutical revealed on the 18th that it has showcased a corporate-customized health management solution, 'Daewoong Healthcare', at the '2025 International Safety and Health Exhibition'. Daewoong presented the Hilliard Core Exercise Center, Cisse, Sun Village, Welda, and Digital Health Care. Hilliard offers customized exercise programs to enhance musculoskeletal management and physical function for employees. Cisse is a wellness brand focused on creating healthy daily life. Sun Village is a healing resort that assists employees in managing mental health through aromatherapy. Welda provides metabolic health management solutions. Digital Health Care can be utilized at in-house clinics or health check-up centers.
ENCell's CEO Jang Jong-wook recently presented on the topic of 'The critical role of CDMO from preclinical to commercialization of cell gene therapies' at the 2025 Advanced Regenerative Medicine Talent Forum, held on the 18th. He analyzed global trends and industries concerning cell gene therapies. He provided insights from his experience and cases since the founding of ENCell, offering suggestions for the advancement of the industry. CEO Jang stated, 'I will ensure that the flow of the bio industry expands into various fields.'
Ildong Pharmaceutical has launched liquid stick-pack over-the-counter drugs, 'Magramin Liquid Double Action' and 'Larafos'. Magramin Liquid Double Action is a magnesium and vitamin B complex supplement. Larafos is an arginine supplement. Both products are easy to carry and consume and are quickly absorbed in the body.
Yonsei University's Yongin Severance Hospital announced on the 18th that it has achieved its 100th robot-assisted breast surgery. Skilled specialists led by Professor Kim Joo-heung are performing robot-assisted breast surgeries. The hospital has established a system that performs all processes, from diagnosis to surgery, chemotherapy, and radiation therapy, within the same institution. Robot breast surgeries make incisions in the armpit, leaving the incision site inconspicuous and attracting attention from patients concerned about changes in appearance.
Hallym University Chuncheon Sacred Heart Hospital recently donated a total of 3 million won, 1.5 million won each, to World Vision Chuncheon General Social Welfare Center and Soyanggang Dam Home Support Center. The donation is part of the 'The Good World Making' project, which involves a volunteer group consisting of hospital staff working together with the local community. The Chuncheon General Social Welfare Center supports essential living items for 50 low-income seniors. The Soyanggang Dam Home Support Center has planned projects to improve the living environment for the elderly.